Annals of Emergency Medicine
Volume 55, Issue 2 , Pages 216-224.e1 , February 2010

Outcome Measures, Interim Analyses, and Bayesian Approaches to Randomized Trials: Answers to the September 2009 Journal Club Questions

  • Aaron M. Brown, MD

      Affiliations

    • University of Pittsburgh Affiliated Residency in Emergency Medicine, Pittsburgh, PA
    • ,
  • David L. Schriger, MD, MPH

      Affiliations

    • University of California, Los Angeles, CA
    • ,
  • Tyler W. Barrett, MD

      Affiliations

    • Vanderbilt University Medical Center, Nashville, TN

References 

  1. Biomarkerssurrogate endpoints. preferred definitions and conceptual framework (Biomarkers Definitions Working Group). Clin Pharmacol Ther. 2001;69:89–95
  2. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed.. New York, NY: Springer Science; 1998;
  3. Rolan P. The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal. Br J Clin Pharmacol. 1997;44:219–225
  4. Sim J, Arnell P. Measurement validity in physical therapy research. Phys Ther. 1993;73:102–115
  5. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA. 1999;282:790–795
  6. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505–1515
  7. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease (The Framingham Study). Am J Med. 1977;62:707–714
  8. Gordon T, Castelli WP, Hjortland MC, et al. Predicting coronary heart disease in middle-aged and older persons (The Framingham Study). JAMA. 1977;238:497–499
  9. Davidson MH, McKenney JM, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774–1781
  10. Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122
  11. Nissen SE, Tardif JC, Nicholls SJ, et al. ILLUMINATE Investigators Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–1316
  12. Ferre RM, Wasielewski JN, Strout TD, et al. Tamsulosin for ureteral stones in the emergency department: a randomized, controlled trial. Ann Emerg Med. 2009;54:432–439
  13. Brenner H. Bias due to non-differential misclassification of polytomous confounders. J Clin Epidemiol. 1993;46:57–63
  14. Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977;105:488–495
  15. Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA. 2003;289:2554–2559
  16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: statistical principles for clinical trials. Stat Med. 1999;18:1905–1942
  17. Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials. 1995;16:395–407
  18. Albers GW. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients?. Neurology. 2000;54:1022–1028
  19. Schriger DL, Herbert ME. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?. Ann Emerg Med. 2001;38:249–255
  20. Neaton JD, Gray G, Zuckerman BD, et al. Key issues in end point selection for heart failure trials: composite end points. J Card Fail. 2005;11:567–575
  21. Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, et al. Composite outcomes can distort the nature and magnitude of treatment benefits in clinical trials. Ann Intern Med. 2009;150:566–567
  22. Connolly HM, Crary J, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–588
  23. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med. 2007;100:187–190
  24. Simmonds MC, Higgins JPT, Stewart LA, et al. Metaanalysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209–217
  25. Reade MC, Delaney A, Bailey MJ, et al. Prospective meta-analysis using individual patient data in intensive care medicine. Intensive Care Med. 2009 Sep 18;[Epub ahead of print]
  26. Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol. 2003;170:2202–2205
  27. Porpiglia F, Ghignone G, Fiori C, et al. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol. 2004;172:568–571
  28. Autorino R, De Sio M, Damiano R, et al. The use of tamsulosin in the medical treatment of ureteral calculi: where do we stand?. Urol Res. 2005;33:460–464
  29. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine, and spasmolytic in medical expulsive therapy for distal ureteral calculi. J Urol. 2005;174:167–172
  30. Taghavi R, Darabi MR, Tavakoli K, et al. Survey of the effect of tamsulosin and nifedipine on facilitating juxtavesical ureteral stone passage. [abstract MP03-06] J Endourol. 2005;19(suppl 1):A9
  31. Yilmaz E, Batislam E, Basar MM, et al. The comparison and efficacy of 3 different a1-adrenergic blockers for distal ureteral stones. J Urol. 2005;173:2010–2012
  32. De Sio M, Autorino R, Di Lorenzo G, et al. Medical expulsive treatment of distal ureteral stones using tamsulosin: a single center experience. J Endourol. 2006;20:12–16
  33. Han MC, Park YY, Shim BS. Effect of tamsulosin on the expectant treatment of lower ureteral stones. Korean J Urol. 2006;47:708–711
  34. Liatsikos EN, Katsakiori PF, Assimakopoulos K, et al. Doxazosin for the management of distal-ureteral stones. J Endourol. 2007;21:538–541
  35. Mohseni MG, Hosseini SR, Alizadeh F. Efficacy of terazosin as a facilitator agent for expulsion of the lower ureteral stones. Saudi Med J. 2006;27:838–840
  36. Porpiglia F, Vaccino D, Billia M, et al. Corticosteroids and tamsulosin in the medical expulsive therapy of symptomatic distal ureter stones: single drug or association?. Eur Urol. 2006;50:339–344
  37. Dal Moro F, Abate A, Lanckriet GR, et al. A novel approach for accurate prediction of spontaneous passage of ureteral stones: support vector machines. Kidney Int. 2006;69:157–160
  38. Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol. 1999;162:688–690
  39. Resim S, Ekerbicer H, Ciftci A. Effect of tamsulosin on the number and intensity of ureteral colic in patients with lower ureteral calculus. Int J Urol. 2005;12:615–620
  40. Hermanns T, Sauermann P, Rufibach K, et al. Is there a role for tamsulosin in the treatment of distal ureteral stones of 7mm or less? results of a randomised, double-blind, placebo-controlled trial. Eur Urol. In press.
  41. Cervenakov I, Fillo J, Mardiak J, et al. Speedy elimination of ureterolithiasis in lower art of ureters with the a1 blocker tamsulosin. Int Urol Nephrol. 2002;34:25–29
  42. Avdoshin VP, Andriukhin MI, Barabash MI, et al. Tamsulosin in the treatment of patients with uteroliths of the lower third of the ureter clinical and pharmacoeconomic grounds. Urologiia. 2005;4:36–39
  43. Barrett TW, Schriger DL. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment: answers to May 2008 Journal Club questions. Ann Emerg Med. 2008;52:458–472
  44. Greenland S. Introduction to Bayesian statistics. In:  Rothman KJ,  Greenland S,  Lash TL editor. Modern Epidemiology. 3rd ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2008;p. 328–344
  45. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. West Sussex, England: John Wiley & Sons Ltd; 2004;
  46. Schriger DL. Problems with current methods of data analysis and reporting, and suggestions for moving beyond incorrect ritual. Eur J Emerg Med. 2002;9:203–207
  47. Howson C, Urbach P. Scientific Reasoning: The Bayesian Approach. La Salle, IL: Open Court; 1989;
  48. Berry DA. Statistics: A Bayesian Perspective. Belmont, CA: Duxbury Press; 1996;
  49. Greenland S. Bayesian perspectives for epidemiological research, I: foundations and basic methods. Int J Epidemiol. 2006;35:765–775

 Section editors: Tyler W. Barrett, MD; David L. Schriger, MD, MPH

 Editor's Note: You are reading answers to the eleventh installment of Annals of Emergency Medicine Journal Club. The questions and the article they are about (Ferre et al. Ann Emerg Med. 2009;54:432-439.) were published in the September 2009 issue.Information about journal club can be found at http://www.annemergmed.com/content/journalclub.Readers should recognize that these are suggested answers. We hope they are accurate; we know that they are not comprehensive. There are many other points that could be made about these questions or about the article in general. Questions are rated “novice,” () “intermediate,” () and “advanced” () so that individuals planning a journal club can assign the right question to the right student. The “novice” rating does not imply that a novice should be able to spontaneously answer the question. “Novice” means we expect that someone with little background should be able to do a bit of reading, formulate an answer, and teach the material to others. Intermediate and advanced questions also will likely require some reading and research, and that reading will be sufficiently difficult that some background in clinical epidemiology will be helpful in understanding the reading and concepts.We are interested in receiving feedback about this feature. Please e-mail journalclub@acep.org with your comments.

PII: S0196-0644(09)01617-5

doi: 10.1016/j.annemergmed.2009.09.027

Annals of Emergency Medicine
Volume 55, Issue 2 , Pages 216-224.e1 , February 2010

Article Tools

* Image Usage & Resolution